Navigation Links
Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
Date:6/1/2009

e sold or promoted in the United States unless and until the FDA has approved a New Drug Application. Similar restrictions apply in other countries.

Recent data from the Phase IIb study demonstrates that the 60-week viral response data continues to show comparable reductions in viral load for weight-based doses of taribavirin and ribavirin in a difficult-to-treat population of patients chronically infected with hepatitis C genotype 1. At the end of week 60, a statistically significantly lower anemia rate for patients receiving taribavirin in the 20mg/kg and 25mg/kg arms versus the ribavirin control arm was maintained at a rate similar to that seen at the end of treatment (week 48).

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the potential efficacy and safety of taribavirin in the treatment of hepatitis C, and the continuing role of ribavirin or taribavirin in the treatment of hepatitis C. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to relating to the clinical development of new products, regulatory approval processes, that interim results fro
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
10. Valeant to Acquire Polish Dermatology Company
11. Valeant Announces Increase to Securities Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/30/2015)... Tucson, AZ (PRWEB) , ... July 31, 2015 , ... ... getaways may seem impossible or out-of-reach. The questions race through your mind: What happens ... is a storm? You feel overwhelmed and cancel your plans. , But not taking ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... On July ... meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately ... event of an overdose is largely perpetuating the heroin crisis in North Florida. The ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... ... Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data ... have been published for use on the CDISC website . These three ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone ... It's for women interested in improving their love lives using specific "lines" designed ... launched to the public early this morning, has drawn praise from several dating ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Conference Call at 10 a.m. EST, January 28, 2008, ... IMA ) and Matria Healthcare, Inc. (Nasdaq: ... definitive agreement pursuant to,which Inverness will acquire all outstanding ... payable $6.50 in cash plus $32.50 in,convertible preferred stock ...
... Surgeons, Jolie, Kidman, Anderson, Loren, Bundchen, Pitt, and ... hear it every day, "Oh, I wish I,could look ... I,d do anything.",With increasing availability of aesthetic plastic surgery, ... some of these wishes are coming true. But do ...
... the first and only co-formulated protease ... use in children with HIV, ABBOTT PARK, Ill., ... that the European Committee for Medicinal Products for Human ... (EMEA),has issued a positive opinion recommending approval of a ...
... Shazaaam! LLC, an integrated,marketing communications agency headquartered ... and Marketing Communications Agency of,Record for Enuresis ... social marketing, proactive and reactive,blogging, traditional and ... and visibility among its target market., ...
... Germany, January 28 Gerresheimer,AG has quickly completed ... Dusseldorf manufacturer of glass and plastic products for ... it continues its global expansion, on 21 December ... Valencia) and Argentina (Buenos,Aires) specialises in pharma containers ...
... The Department of Defense has commissioned a nine-month study ... Medical Center to determine whether a new drug based ... of acute radiation injury following radiation exposure. The new ... was greater than 5,000 times more effective at reducing ...
Cached Medicine News:Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 2Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 3Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 4Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 5Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 6Health News:Celebrity Influences on Plastic Surgery 2Health News:Celebrity Influences on Plastic Surgery 3Health News:Celebrity Influences on Plastic Surgery 4Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 2Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 3Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 4Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 5Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 6Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 7Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 8Health News:Shazaaam! Named PR Agency of Record for Enuresis Treatment Center 2Health News:Feds fund study of drug that may prevent radiation injury 2
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... COTTAGE, New York , July 30, 2015 /PRNewswire/ ... release of its latest report titled, "Continuous Glucose Monitoring ... - 2020". According to the report, the global continuous ... Mn in 2014 and is expected to reach US$ ... during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... MIAMI , July 30, 2015   ... latest update to UNI®, the world,s first operating ... simulators, is now available exclusively to Gaumard users. ... for recently launched Newborn Tory™ S2200, as well ... and monitoring of clinical measures such as EtCO ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... N.J., Jan. 18, 2011 Fenwal, Inc. of Lake ... they have signed an agreement under which Fenwal will ... blood centers, plasma centers and hospitals in the United ... such as Genesis™ blood collection mixers and monitors, RapidSeal ...
... Inc. announced today that the U.S. Food & ... clearance to market the SImmetry™ Sacroiliac Joint Fusion ... intended for treating conditions including degenerative sacroiliitis and ... System consists of a range of threaded, cannulated ...
Cached Medicine Technology:Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... proof polypropylene exhaust hoods are designed to ... and draw a stream of air across ... the operator. Other sizes and types of ... double-slot are available on special order in ...
... This fume hood is the ... but includes a flat internal ... the shell. The baffle slopes ... air flow to sweep the ...
... polypropylene exhaust hoods are designed to rest ... draw a stream of air across the ... operator. Other sizes and types of hoods ... are available on special order in materials ...
Medicine Products: